tiprankstipranks
BerGenBio Reports Progress in Cancer Drug Development
Company Announcements

BerGenBio Reports Progress in Cancer Drug Development

BerGenBio ASA (BRRGF) has released an update.

Don't Miss our Black Friday Offers:

BerGenBio ASA has reported progress in its focused approach to develop bemcentinib for first-line treatment in NSCLC patients with STK11 mutations, highlighting the completion of Phase 1b enrollment and ongoing progress of the Phase 2a study. The company has decided to discontinue its tilvestamab activities, while maintaining a healthy financial position with cash reserves of NOK 174.8 million. Investors can expect an interim analysis of the bemcentinib study in early 2025.

For further insights into BRRGF stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks European Auto-Generated NewsdeskBerGenBio Highlights Clinical Progress and Strategy
TipRanks European Auto-Generated NewsdeskBerGenBio ASA Appoints New CEO to Lead Growth
TipRanks Auto-Generated NewsdeskBerGenBio Reports Q3 2024 Earnings and Strategy Updates
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App